NMX 2
Alternative Names: NMX-2Latest Information Update: 12 Nov 2022
At a glance
- Originator NovoMedix
- Class Antifibrotics; Antihyperglycaemics; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Extracellular signal-regulated MAP kinase inhibitors; Interleukin 11 inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis; Type 2 diabetes mellitus